Dose Escalation Study of PF-07209326 in Healthy Participants and Participants With Sickle Cell Disease

Completed · Phase 1 · Has a placebo group

Conditions studied: Healthy, Sickle Cell Anemia

In brief

This Phase 1 first-in-human, first-in-patient, single ascending dose and multiple dose study will be a randomized, double-blind, placebo-controlled investigation of the safety, tolerability, and pharmacokinetics of PF-07209326 in healthy participants and participants with sickle cell disease.

Key facts

Study ID
NCT04255875
Run by
Pfizer
People needed
52
Starts
2020-02-05
Expected to finish
2023-07-07
Last updated by the study team
2026-06-15

Who can join

Age: 16 and older, up to 70. Sex: any. Healthy volunteers: accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.